Effective improvement of minimal change nephrotic syndrome with uncontrollable high low-density lipoprotein cholesterol level using evolocumab accompanied by the development of acute pancreatitis
- 1 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in CEN Case Reports
- Vol. 9 (4), 333-337
- https://doi.org/10.1007/s13730-020-00481-x
Abstract
Nephrotic syndrome is sometimes refractory; however, it is rarely accompanied by acute pancreatitis. A 47-year-old Japanese woman complaining of limb edema was diagnosed with nephrotic syndrome. Blood and urine examinations suggested minimal change nephrotic syndrome (MCNS), and pulse intravenous methylprednisolone was administered, followed by oral prednisolone. Although proteinuria improved, the patient’s condition remained unchanged, and diuresis was insufficient. As in patients with other nephrotic syndromes, this patient showed significant dyslipidemia. Atorvastatin was started for remarkable dyslipidemia since her admission, but her low-density lipoprotein cholesterol (LDL-C) level did not improve significantly. During the clinical course, she developed acute pancreatitis, and large-volume fluid replacement was performed. Although diuretic levels were increased in response to the increased fluid volume, diuresis was not enough, and lung edema developed. Extracorporeal ultrafiltration was started to ameliorate the lung edema. With the onset of pancreatitis, oral intake, including atorvastatin, was discontinued, and prednisolone was administered intravenously. To treat the high-LDL cholesterolemia, 140 mg of evolocumab was injected subcutaneously. Nausea slightly decreased on the following day, and the administration of 150 mg cyclosporine was initiated. LDL-C levels, proteinuria, and renal function promptly ameliorated. The results of a renal biopsy suggested MCNS. On the 44th day of hospitalization, she had complete remission. Evolocumab is potentially effective for severe nephrotic syndrome with uncontrollable dyslipidemia.Keywords
This publication has 20 references indexed in Scilit:
- Association of Oral Glucocorticoid Use With an Increased Risk of Acute PancreatitisJAMA Internal Medicine, 2013
- Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysisAnnals Of The Rheumatic Diseases, 2012
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- Drug-Induced Acute Pancreatitis: An Evidence-Based ReviewClinical Gastroenterology and Hepatology, 2007
- Antihypertensive medication and the risk of acute pancreatitis: The European case-control study on drug-induced acute pancreatitis (EDIP)Scandinavian Journal of Gastroenterology, 2006
- Glucocorticoid receptor expression is down-regulated by Lp(a) lipoprotein in vascular smooth muscle cells.Endocrinology, 1995
- The increased risk of coronary heart disease associated with nephrotic syndromeKidney International, 1993
- Effect of VLDL on the inhibition of arachidonic acid transformation by dexamethasone in cultured smooth muscle cellsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- Increased serum pancreatic enzymes after treatment with methylprednisolone: possible evidence of subclinical pancreatitis.BMJ, 1985
- DRUG-ASSOCIATED PRIMARY ACUTE PANCREATITISThe Lancet, 1978